$PRME News
Last published 22h ago
- 22h agoPRMEPrime Medicine Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share. Prime Medicine has also granted the underwrit ...
- 1d agoPRMEPrime Medicine, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 1d agoPRMEPrime Medicine Announces Proposed $125.0 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purc ...
- 2d agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 1mo agoPRMEMorgan Stanley 24th Annual Global Healthcare Conference - PRIME MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everyone. My name is Chris Yu. I'm on Terrence Flynn's team covering biopharma and biotech companies. I am delighted to host Alan Ryan, CEO of Prime Medicine. Before we start, for important discl
- 1mo agoPRMEPrime Medicine - 1773617 - PRIME MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everyone. My name is Chris Yu. I'm on Terrence Flynn's team covering biopharma and biotech companies. I am delighted to host Alan Ryan, CEO of Prime Medicine. Before we start, for important discl
- 2mo agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 3mo agoPRMEPrime Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable
- 3mo agoPRMEPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson DiseaseGlobeNewswire-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent
- 4mo agoPRMEPrime Medicine Announces Positive Resolution to Arbitration with Beam TherapeuticsGlobeNewswire-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to
- 4mo agoPRMEPrime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)GlobeNewswire-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47phox-deficient CGD
- 4mo agoPRMEPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson DiseaseGlobeNewswire-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --
- 5mo agoPRMEPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 5mo agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 6mo agoPRMEPrime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward
- 6mo agoPRMEPrime Medicine Appoints Svetlana Makhni as Chief Financial OfficerGlobeNewswireCAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 7mo agoPRMEMDGLIOVADNLIThe $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepPR NewswireThe FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell...
- 7mo agoPRMEMDGLIOVADNLIAdvanced Cell-based Therapy Booming the Success for Healthcare SectorPR NewswireUSANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578...
- 8mo agoPRMEPrime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to
- 8mo agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 10mo agoPRMEPrime Medicine to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 10mo agoVRTXCRSPPRMEMDGLGene Therapy: 5 Biotech Stocks Chasing the $36B PrizePR NewswireEquity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments...
- 11mo agoPRMEPrime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseGlobeNewswireCAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 11mo agoPRMEPrime Medicine to Present at 8th Annual Evercore Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMECORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development
- 1y agoPRMEPrime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate
- 1y agoPRMEPrime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business OfficerGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease StrategyGlobeNewswireCAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoPRMEPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on
- 1y agoPRMEPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Pricing of Public OfferingGlobeNewswireCAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisGlobeNewswire-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership TransitionGlobeNewswire-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's
- 1y agoPRMEPrime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous DiseaseGlobeNewswire-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66%
- 1y agoPRMEPrime Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND
- 1y agoPRMEPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewswire-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing
- 1y agoPRMEPrime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 --
- 1y agoPRMEPrime Medicine to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 1y agoPRMEKuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME)...
- 1y agoPRMEPrime Medicine to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire-- Presented initial in vivo data for universal liver-targeted LNP and Wilson's Disease program at ESGCT; initiated IND-enabling activities for Wilson's Disease program in 4Q 2024 and remains on track to file IND and/or
- 2y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 2y agoPRMEPrime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual CongressGlobeNewswireDelivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate